Join us in Boston on June 10-12 for Cancer Immunotherapy: From Bench to Bedside and Back.

Hear from experts from across the field of cancer immunotherapy as they present the latest biological, technological, translational, & clinical advances.

Tickets: ms.spr.ly/6017chSgt

Life can change in an instant. That's why advance care planning is so important. Today is #NationalHealthcareDecisionsDay . Our palliative care team at Dana-Farber helps patients take control of their own health and teaches them how to start those tough conversations.

Congratulations to Erica Mayer ⁦for the Dana-Farber Innovation Award - Nancy Lin, MD
Erica Mayer Dana-Farber’s Breast Oncology Center

#Cancer #DanaFarber #Health #OncoDaily #Oncology

oncodaily.com/48118.html

Extremely important topic. Watching this 7 minutes video can empower your role and contribute to eliminate inequities for breast cancer treatment.
⬆️ early detection in developing countries
⬇️ educate disparities about cancer
⬇️ cost of life saving drugs in low income countries

Thank you so much to Sírio-Libanês for inviting me tonight to the 2024 Breast Cancer Excellence event. We discussed applications of #artificialintelligence in #healthcare , the #biases we should be aware of, and the #challenges ahead! #bcsm #digitalhealth #HealthEquity

Last week, Zakim Co-Director Ting Bao, MD chaired the Oral Abstract Session on Acupuncture Research at the 2024 International Congress on Integrative Medicine and Health, the most comprehensive scientific congress in the field of #integrativemedicine IMConsortium

The 2nd Annual #DCIS Patient Forum will be held virtually on Sat, May 18th at 9 am!

A variety of topics will be covered including
👉understanding your pathology report
👉radiation therapy for DCIS
👉+ all sessions will have a Q&A component

Register: redcap.partners.org/redcap/surveys…

Best of luck to all Dana-Farber Marathon Challenge runners today in the #BostonMarathon . We are deeply grateful to all our runners, supporters, and volunteers. Together we are advancing discoveries and treatments for patients with cancer everywhere.

Here's the newest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (April 8th-14th, 2024). #ClinicalResearch #CancerTreatment #BCSM #BreastCancer Research

Good Luck 2024 Dana-Farber Marathon Team! 🏃‍♀️🏃‍♂️
And a special shout out to Anne Keane, (@adjewelry) a #Stage4BreastCancer patient advocate, who is running her 3rd #BostonMarathon today! There is still time to support her 👇👇
danafarber.jimmyfund.org/site/TR?fr_id=…

Second primary breast cancer among young (≤40 yr) stage 0-III breast cancer survivors
JAMA Oncology

At median 10 years
✅2.2% for women who did not carry a germline pathogenic variant
🚨8.9% for carriers of a pathogenic variant
➡️PV carriers vs noncarriers sHR: 5.27( 1.43-19.43)…

Good luck to all Dana-Farber colleagues, friends and families from all over the 🌎 who are running the Boston Marathon tomorrow.

Together we can beat cancer !

The Jimmy Fund Dana-FarberNews

Anna Weiss showing improved pt understanding of CBC risk after quantitative genetic counseling but ultimately didn’t impact their decision for CPM. ASBrS #ASBrS24

Yes ! Over half of all U.S. FDA approved drugs ! Dana-Farber The Jimmy Fund Pan-Mass Challenge Dana-FarberNews

Thank you Dr. Helen Pass for reviewing the best papers of 2023 and highlighting that management of the axilla requires multidisciplinary, patient centered input! ASBrS #ASBrS24

Andrea Merrill, MD FACS ASBrS Best slide of #ASBrS24 ?

Approximately 60% of all HER2- breast cancers are currently defined HER2-low (IHC 1+ or 2+ ISH-). This review describes how to best identify pts with HER2-low breast cancer with respect to sample type, testing methods, scoring and reporting of HER2 status. esmoopen.com/article/S2059-…

In our latest article we review best practices & future perspectives for the identification of pts with HER2-low BC. Thanks to AZ for support and to H. Earle for bravely sharing with us and the ESMO Open readers her experience during treatment with T-DXd. esmoopen.com/article/S2059-…

Launch of the Third Transatlantic exchange in Oncology in Boston. 🇺🇸

Dana-Farber and Gustave Roussy are proud to share their progress in #cancer treatment.

🎯 This third edition will be dedicated to Liquid biopsy as en emerging approach in precision cancer medicine.

BREAKING: U.S. FDA’s ODAC Recognizes MRD as an Accepted End Point for Accelerated Approval in Multiple Myeloma #mmsm #oncology onclive.com/view/fda-s-oda…